Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 15:07:58 2024-06-18 EDT 5-day change 1st Jan Change
133.9 USD -2.93% Intraday chart for Moderna, Inc. -9.79% +34.61%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
FDA asks COVID vaccine makers to target KP.2 strain with updated shots RE
Moderna: successful trial for new Covid vaccine CF
Moderna's New COVID-19 Vaccine Meets Primary Efficacy Endpoint MT
Moderna Says its Phase 3 Trial of mRNA-1283 Meets Primary Vaccine Efficacy Endpoint Against COVID-19 MT
Moderna's next-gen COVID vaccine shows non-inferiority to current shot RE
Moderna, Inc. Announces Positive Phase 3 Efficacy Data for mRNA-1283 CI
Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says MT
JPMorgan Raises Price Target on Moderna to $96 From $85 MT
Oppenheimer Raises Price Target on Moderna to $179 From $163 MT
Moderna Insider Sold Shares Worth $30,087,339, According to a Recent SEC Filing MT
Health Care Up on Defensive Bias -- Health Care Roundup DJ
Sector Update: Health Care Stocks Advance Late Afternoon MT
Sector Update: Health Care Stocks Retreat Monday Afternoon MT
Sector Update: Health Care MT
Transcript : Moderna, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 01:20 PM
Top Midday Stories: Elliott Amasses $2 Billion Stake in Southwest; SCOTUS to Review Meta Investor Data-Harvesting Suit; Blackstone Competes Tropical Smoothie Acquisition MT
Moderna's Combination Flu, COVID-19 Shot Triggers High Immune Responses in Late-stage Study MT
Moderna's Combined Influenza, COVID-19 Shot Elicits 'Higher Immune Response' Versus Others, Drugmaker Says MT
Exchange-Traded Funds, Equity Futures Retreat Pre-Bell Monday Ahead of Key Economic Data, FOMC Announcement MT
Moderna: phase 3 trial of an experimental vaccine CF
Moderna Says Combination Vaccine Shows Higher Immune Response Against Flu, Covid-19 in Phase 3 Trial MT
Moderna, Inc Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19 CI
Moderna COVID/flu combo vaccine superior to separate shots in trial RE
US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59 RE
Moderna Files With FDA for Updated Covid Shot DJ
Chart Moderna, Inc.
More charts
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
137.9 USD
Average target price
145.2 USD
Spread / Average Target
+5.31%
Consensus
  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. News Moderna, Inc.
  5. Oppenheimer Adjusts Price Target on Moderna to $163 From $142